✦ LIBER ✦

Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study

✍ Scribed by Spigel, David R.; Waterhouse, David M.; Lane, Steve; Legenne, Philippe; Bhatt, Kamal

Book ID: 120287065
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 401 KB
Volume: 14
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2012.12.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II multicenter study of combined

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer

✍ Joppert, M 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 101 KB

An open-label, single-arm Phase II study

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Open, Randomized, Phase II Study of Sing

Open, Randomized, Phase II Study of Single-Agent Gemcitabine and Docetaxel as First- and Second-Line Treatment in Patients with Advanced Non–Small-Cell Lung Cancer

✍ Christian Manegold; Gabriele Koschel; Dagmar Hruska; Kathrin Schott-von-Römer; J 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 155 KB

Phase II Study of Efficacy and Safety of

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non Small-Cell Lung Cancer

✍ Herbst, R. S.; O'Neill, V. J.; Fehrenbacher, L.; Belani, C. P.; Bonomi, P. D.; H 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 144 KB

Efficacy and safety of erlotinib versus

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

✍ Tudor Ciuleanu; Lilia Stelmakh; Saulius Cicenas; Skaidrius Miliauskas; Alexandru 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 381 KB

Prospective, multicenter, randomized, in

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

✍ Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 316 KB